Previous Article | Next Article 
Molecular and Cellular Biology, November 1998, p. 6191-6200, Vol. 18, No. 11
0270-7306/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.
Sp1-Mediated Transcription of the Werner Helicase
Gene Is Modulated by Rb and p53
Yukako
Yamabe,1
Akira
Shimamoto,1
Makoto
Goto,2
Jun
Yokota,3
Minoru
Sugawara,1 and
Yasuhiro
Furuichi1,*
AGENE Research Institute, Kamakura, Kanagawa
247,1
Tokyo Metropolitan Otsuka
Hospital, Minami Otsuka, Toshima-ku, Tokyo 170,2
and
National Cancer Center, Chuo-ku, Tokyo
104,3 Japan
Received 3 April 1998/Returned for modification 23 June
1998/Accepted 12 August 1998
 |
ABSTRACT |
The regulation of Werner's syndrome gene (WRN)
expression was studied by characterizing the cis-regulatory
elements in the promoter region and the trans-activating
factors that bind to them. First, we defined the transcription
initiation sites and the sequence of the 5' upstream region (2.8 kb) of
WRN that contains a number of cis-regulatory
elements, including 7 Sp1, 9 retinoblastoma control element (RCE), and
14 AP2 motifs. A region consisting of nucleotides
67 to +160 was
identified as the principal promoter of WRN by reporter
gene assays in HeLa cells, using a series of WRN
promoter-luciferase reporter (WRN-Luc) plasmids that contained the
5'-truncated or mutated WRN upstream regions. In
particular, two Sp1 elements proximal to the transcription initiation
site are indispensable for WRN promoter activity and bind specifically to Sp1 proteins. The RCE enhances WRN promoter activity.
Coexpression of the WRN-Luc plasmids with various dosages of plasmids
expressing Rb or p53 in Saos2 cells lacking active Rb and p53 proteins
showed that the introduced Rb upregulates WRN promoter
activity a maximum of 2.5-fold, while p53 downregulates it a maximum of
7-fold, both dose dependently. Consistently, the overexpressed Rb and
p53 proteins also affected the endogenous WRN mRNA levels
in Saos2 cells, resulting in an increase with Rb and a decrease with
p53. These findings suggest that WRN expression, like that
of other housekeeping genes, is directed mainly by the Sp1
transcriptional control system but is also further modulated by
transcription factors, including Rb and p53, that are implicated in the
cell cycle, cell senescence, and genomic instability.
 |
INTRODUCTION |
Werner's syndrome (WS) is a rare
autosomal recessive genetic disorder causing symptoms of premature
aging, such as gray hair, baldness, cataracts, and osteoporosis
(9, 15, 23), accompanied by rare cancers (14). In
vitro studies of fibroblast growth characteristics also suggest that WS
may be related to normal aging: the life span of WS fibroblasts as
expressed by population doubling levels is much shorter than that of
normal fibroblasts (10, 32). The hypermutator phenotype,
such as represented by genetic instability, also occurs frequently in
WS fibroblasts and lymphoid cells (27, 31, 33, 41).
The gene responsible for WS (WRN) has been identified by
positional cloning from the 8p11-p12 region (48) and is
composed of a total of 35 exons (25, 49) that generate mRNA
with 5,189 nucleotide residues. We have recently demonstrated that the
gene product of WRN is an active RecQ-type DNA helicase by
expressing WRN in insect cells, and we postulated that
defective DNA metabolism is involved in a complex process of premature
aging in WS patients (40). DNA helicases are enzymes that
unwind the energetically stable double-stranded structure of DNA to
provide the single-stranded template for important cellular processes
such as replication, recombination, and repair (42).
Mutations occurring in more than 100 WS patients have been extensively
investigated by us and others. The more than 19 different types of
mutations identified to date are distributed over the entire coding
region of WRN and exist in individual patients as either
homozygous or compound heterozygous mutations (13, 25, 48,
49). We recently found that most of these mutations generate truncated DNA helicase molecules lacking the nuclear localization signals in the C-proximal region, rendering the WRN products
unable to be transported to the nucleus, where the DNA helicase is
believed to function (26). This finding not only explains
why WS patients with different types of mutations manifest similar
clinical phenotypes but also suggests that WRN expression in
patient cells is totally inhibited at the stage of protein
transportation. Thus, to understand the molecular mechanism underlying
WS, elucidation of the regulation of WRN transcription,
which prevents individuals without WS from premature aging, is
imperative.
The WRN mRNA is expressed in many organs but shows some
organ-specific features, e.g., high expression in testis, ovary, and pancreas and low expression in lung, brain, kidney, and leukocytes (reference 48 and our unpublished results).
Regarding the levels of WRN mRNA in healthy individuals and
WS patients, we recently reported that both fibroblasts and
Epstein-Barr virus-transformed B-lymphoblastoid cell lines from
patients with homozygous mutation 4 or mutation 6 had much less mRNA
than normal cells. This reduction in the WRN mRNA level
suggested an augmented specific degradation of the WRN mRNA
in patient cells, as was shown in other cases in which the nonsense
codons affected RNA metabolism in vertebrate cells (47).
However, little is known about the various aspects of WRN
transcription, for example, the promoter, its cis-acting elements, and trans-activating protein factors, such as Rb,
p53, and Sp1, that regulate WRN expression as discussed in
this report.
The tumor suppressor proteins Rb and p53 are nuclear phosphoproteins
involved in the control of cell proliferation and regulation of the
cell cycle. The Rb and p53 proteins have been shown to act positively
or negatively in the transcriptional regulation of various cellular
genes. Rb interacts with several transcription factors, such as E2F and
ATF2, to modulate their activity as was shown for transforming growth
factor
2 gene (TGF-
2) expression (5, 20).
Rb also regulates Sp1-mediated transcription through the retinoblastoma
control element (RCE) motif by interacting directly with Sp1-I (a
negative regulator of Sp1) and by liberating the Sp1 transcription
factor from Sp1-Sp1-I complexes (6, 44). The RCE motif
exists in several growth-related genes, such as c-fos and
TGF-
1, and regulates transcription positively or
negatively, depending on the cell type (19, 30). By
contrast, control by p53 is known to depend on promoter sequence; it
activates transcription of the p21/WAF1, GADD45,
and mdm2 genes by binding to the p53 response elements in
their promoter regions (17). Conversely, p53 represses other
genes, such as c-fos and topoisomerase II
, that lack the p53 response element (21, 45). Transcriptional repression by p53 is mediated by protein-protein interactions, such as
with the TATA-binding protein, the CAAT-binding factor, or the Sp1
transcription factor, resulting in the inactivation of their
trans-activating abilities (1, 4, 11, 46).
In this study, we elucidated the functional cis-acting
elements in the WRN promoter and demonstrated that
trans-activating factors Sp1, Rb, and p53 control
WRN expression. Knowledge obtained from these studies should
contribute to our understanding of the regulation of WRN
expression in vivo.
 |
MATERIALS AND METHODS |
Cell lines.
HeLa cells (epithelioid carcinoma, cervix) were
used for reporter gene assays. Saos2 cells (osteosarcoma) that lacked
active Rb and p53 proteins were used for assaying the effects of these proteins on the WRN promoter. Two Saos2 cell lines, SRb-7
and Sp53-3 (29), that carry the tetracycline-inducible
expression plasmids for Rb and p53, respectively, were made by one of
us (J.Y.) and used to examine the individual effects of Rb and p53 on
WRN transcription. All cell lines were maintained in
Dulbecco's modified Eagle's medium supplemented with 10%
heat-inactivated fetal calf serum. The culture medium for SRb-7 and
Sp53-3 contained hygromycin B (0.3 mg/ml), G418 (0.5 mg/ml), and
tetracycline (1 µg/ml). The cell lines were cultured at 37°C in an
incubator with 5% CO2.
Determination of transcription start sites.
The
transcription start sites of WRN mRNA were determined by an
oligonucleotide-capping method (36), with slight
modification. Briefly, the cap structure of poly(A)+ RNA
obtained from HeLa cells was removed by highly purified tobacco acid
pyrophosphatase (Nippon Gene), and decapped mRNA was ligated to the RNA
linker 5'-CGAAUCGUAACCGUUCGUACGAGAAUCCGCU-3' by using T4 RNA
ligase. The product was then reverse transcribed by using a random
hexamer and was amplified by PCR using a combination of the RNA
linker-specific primer 5'-ATCGTAACCGTTCGTACGAGAATCGC-3' and
the WRN-specific primer
5'-CCCACCACATCCCCATCTGATAGACTC-3' (positions 453 to 479),
followed by the WRN-specific nested primer 5'-AGGAAAGAGCAATCACTAGCATCG-3' (positions 411 to 434). The
PCR product was cloned into the pGEM-T vector (Promega), and the
nucleotide sequence encompassing the capping site of WRN
mRNA was determined after sequence analysis by PCR-based cycle
sequencing using a Prism sequencing kit (Perkin-Elmer) with 17 independent clones. The S1 nuclease mapping analysis described by Berk
and Sharp (3) was performed to confirm the transcription
initiation sites obtained by the oligonucleotide-capping method. A
5'-32P-labeled DNA fragment (245 bp, encompassing
nucleotide residues
143 to +102) was prepared by EcoO109I
and BssHII digestion and by subsequent 5'-end labeling with
[
-32P]ATP and T4 polynucleotide kinase. The labeled
duplex DNA fragment (106 cpm) was purified on a Centrisep
column (Applied Biosystem), denatured by boiling followed by chilling,
and hybridized to the total RNA (25 µg) from human K562 cells. As a
control, yeast tRNA (25 µg) was also used in place of K562 cell RNA.
Hybridization conditions were heating at 80°C for 10 min and
annealing at 50°C for 3 h in hybridization buffer [50 mM
piperazine-N,N'-bis(2-ethanesulfonic acid)
(PIPES)-NaOH buffer (pH 6.4), 1 mM EDTA, 80% formamide, 0.4 M NaCl].
The annealed RNA-DNA heteroduplex was digested in S1 digestion buffer
containing 30 mM sodium acetate buffer (pH 4.6), 280 mM NaCl, 1 mM
ZnSO4, 100 µg of salmon sperm DNA per ml, and 1,000 U of
S1 nuclease per ml (TaKaRa) at 37°C for 30 min, and the reaction
products were analyzed by 5% polyacrylamide gel electrophoresis.
P1/PAC DNA and determination of DNA sequences.
The
P1/P1-derived artificial chromosome (PAC) library was screened by a
PCR-based strategy, and positive clones were isolated by Genome
Systems, Inc. (St. Louis, Mo.). PAC 12339 DNA was isolated by an
alkaline lysis procedure essentially described by Smoller et al.
(38), with slight modification, and purified by density equilibrium centrifugation with CsCl-ethidium bromide gradients. After
digestion with Sau3AI, the PAC 12339 DNA was subcloned into the BamHI site of pBluescriptII KS(+) (Stratagene). To
obtain the promoter region, this DNA library was screened by PCR using primers designed from the sequence of the first exon of WRN:
5'-GGGAATAAAGTTTGCTGATTT-3' (positions 50 to 70) and
5'-CAGTCCAACAGGTCTTCTTCA-3' (positions 134 to 154). The
sequences of nine positive clones were determined. Sequence homology to
any other known human genomic DNA was analyzed by Intelligenetics
software and the FASTA and TFASTA programs from the Genetics Computer
Group database searching software package (2).
Construction of WRN-Luc plasmids for promoter assay.
After
the pBS/12339-17 plasmid DNA containing the putative promoter region of
WRN was digested with BamHI, the 2,776-bp insert fragment was placed at the BglII site of the pGL3-Basic
vector (Promega) upstream of the firefly luciferase gene, which was
used as a reporter gene (pGL3/A). To generate a series of 5'-deletion mutants, the WRN promoter region of pGL3/A was digested with
SacI/XhoI and then treated with exonuclease III
and mung bean nuclease (pGL3/B to -N), or was amplified by PCR with
specific primers, and was placed back into the pGL3-Basic plasmid
(pGL3/O to -R), yielding what we refer to as the WRN-Luc plasmids.
Mutations with base substitutions were made for each Sp1 element and/or
RCE motif by using an LA PCR in vitro mutagenesis primer set for
pBluescriptII (TaKaRa) according to the manufacturer's protocol
(creating pGL3/S3m, -S2m, -S1m,
-S32m, -S321m, -S3m/Rm, -S32m/Rm,
-S321m/Rm, and -Rm). To generate the 3'-deleted pGL3/O and
pGL3/S321m/Rm mutants missing residues 20 to 160, the
plasmids were digested simultaneously at nucleotide position 20 by
BglI and upstream of the vector by MluI, and the
excised fragment was ligated to the SmaI site of the
pGL3-Basic vector (yielding pGL3/O
3' and
pGL3/S321m/Rm
3'). The directions and sizes of the
modified promoter region of all constructs were confirmed by DNA
sequencing.
DNA transfection and luciferase assay.
HeLa and Saos2 cell
lines were transfected by the lipofection method as described by
Felgner et al. (12). Briefly, the WRN-Luc plasmid DNAs (1 µg) and a plasmid (pRL-TK; Wako Pure Chemicals, Osaka, Japan)
containing the herpes simplex virus thymidine kinase promoter and sea
pansy luciferase (0.1 µg) used as an internal control were mixed with
Lipofectin reagent (GIBCO BRL) and cotransfected into target cells
grown to 60 to 70% confluence in six-well plates. After 5 h of
incubation with the Lipofectin-DNA complex, the cells were washed twice
in medium containing serum and cultured for 48 h. The cells were
then lysed and assayed for firefly and sea pansy luciferase activities
separately, using a double-luciferase assay system (Wako Pure
Chemicals) and LUMAT LB 9507 luminometer (EG&G Bertholdo). The activity
of the WRN promoter evidenced by firefly luciferase activity
was evaluated after normalizing for small differences in transfection
efficiency by the sea pansy luciferase activity. Expression plasmids
that produce Rb (pCMV1-Rb), wild-type p53 (pC53-SN3), and mutant p53
(pC53-249) were kindly provided by Eiji Hara (Kyoto Prefectural Medical
School) and Takashi Uchida (Nippon Roche Research Institute). In the Rb
or p53 overexpression experiments, the WRN-Luc plasmid DNAs (1 µg),
the Rb or p53 expression plasmid (0.03 to 5 µg), and pRL-TK (0.1 µg) were cotransfected and assayed for luciferase activity as
described above.
Preparation of nuclear extracts from HeLa cells.
Nuclear
extracts were prepared essentially as described by Dignam et al.
(8) from confluent cultures of HeLa cells. Approximately 108 cells were washed with ice-cold phosphate-buffered
saline, pelleted, and resuspended in 10 mM Tris-HCl (pH 7.9)-1.5 mM
MgCl2-10 mM KCl-0.5 mM dithiothreitol (DTT). After
incubation on ice for 10 min, the cells were homogenized in a Dounce
homogenizer with approximately 20 strokes. The nuclei were then
pelleted and resuspended in 20 mM Tris-HCl (pH 7.9) buffer containing
1.5 mM MgCl2, 20% glycerol, 0.5 mM DTT, 0.3 M KCl, and 0.5 mM phenylmethylsulfonyl fluoride (PMSF). After rocking at 4°C for 30 min, the supernatant was dialyzed for 2 h at 4°C against 4 liters of 20 mM Tris-HCl (pH 7.9) buffer containing 0.1 M KCl, 0.2 mM
EDTA, 20% glycerol, 0.5 mM DTT, and 0.5 mM PMSF. The extracts were
mixed with a cocktail of protease inhibitors to final concentrations of
1 mM PMSF, 1 mM EGTA, 0.021 mM leupeptin, 0.01 mM pepstatin, 0.1 mM
N
-p-tosyl-L-lysine chloromethylketone (TLCK)
and 1 mM N-methylmaleimide, aliquoted, and stored at
70°C until used. The protein concentration was measured by using a Pierce bicinchoninic acid protein assay kit.
EMSA.
Electrophoretic mobility shift assays (EMSAs) were
done as described by Singh et al. (37), with slight
modifications. A HeLa cell nuclear extract (2 to 5 µg) was first
incubated in 10 mM Tris-HCl (pH 7.5) buffer containing 50 mM NaCl, 0.5 mM DTT, 0.5 mM EDTA, 1 mM MgCl2, 0.4 mg of bovine serum
albumin per ml, 4% glycerol, and 50 to 250 µg of double-stranded
poly(dI-dC) (Pharmacia, Piscataway, N.J.) per ml for 20 min at room
temperature. The mixture was then incubated for an additional 20 min
with approximately 10,000 cpm of double-stranded
32P-labeled oligonucleotides containing Sp1-3 (positions
86 to
57), RCE (positions
70 to
51), Sp1-2 (positions
65 to
36), or Sp1-1 (positions
46 to
17). In the competition
experiments, a 50-fold molar excess of specific (Sp1) or nonspecific
(AP1) competitor (nonradioactive oligonucleotides; see below) was
incubated with the HeLa cell nuclear extract before addition of
32P-labeled oligonucleotides. The competitor
oligonucleotides (only sense strands are shown) were
5'-ATTCGATCGGGGCGGGGCGAGC-3' for Sp1 and
5'-CGCTTGATGAGTCAGCCGGAA-3' for AP1. For the supershift experiment, the nuclear extract was preincubated with 0.5 mg of Sp1-specific polyclonal antibody or nonimmunized rabbit immunoglobulin G (IgG) fraction (Santa Cruz Biotechnology, Inc.) per ml at 4°C for
1 h. The antibody-treated extract was used for the EMSAs as described above. The reaction mixtures were electrophoresed in a 4%
polyacrylamide gel in 0.5× TBE buffer (45 mM Tris-borate, 1 mM EDTA
[pH 8.0]) at 100 V for 2.5 h and were analyzed for retardation of labeled oligonucleotides during electrophoretic migration. After
drying, the gels were exposed to X-ray film (Kodak) at
70°C with
intensifying screens for 24 to 48 h.
Northern blot analysis.
Two Saos2 cell lines, SRb-7 and
Sp53-3 (29), that carry the tetracycline-inducible
expression plasmids for Rb and p53, respectively, were cultured in the
presence or absence of tetracycline at 37°C for 6 to 12 h. The
poly(A)+ RNA was extracted from these cells by the acid
guanidinium thiocyanate-phenol-chloroform extraction method
(7) and Oligotex-d(T)30 (Takara Co. Ltd., Osaka, Japan).
Three micrograms of poly(A)+ RNA was electrophoresed in 1%
agarose gels containing formamide and transferred to Hybond-N membranes
(Amersham). Hybridization was performed with
32P-radiolabeled probe (2 × 106 cpm/ml)
prepared from the C-terminal region, which includes the 3' untranslated
region (nucleotide residues 3199 to 5065) of the WRN gene,
at 42°C for 16 h. Then the membranes were washed in 0.2× SSC
(1× SSC is 0.15 M NaCl plus 0.015 M sodium citrate)-0.1% sodium
dodecyl sulfate at 42°C for 30 min and autoradiographed for 5 days.
For quantitative analysis, the membranes were stripped and then
rehybridized with a 32P-radiolabeled
-actin probe as a
control to normalize the density. The relative intensities of
individual WRN mRNA bands were estimated with a BAS-1500
Bioimaging Analyzer (Fujifilm).
Nucleotide sequence accession number.
The complete
nucleotide sequence of the 2.8-kb WRN fragment was deposited
in the GenBank/EMBL Data Bank with accession no. AB003173.
 |
RESULTS |
Identification of the transcription start sites of WRN.
Before identifying the WRN promoter region, we analyzed the
transcriptional start sites of WRN by the
oligonucleotide-capping method described in Materials and Methods.
Primers were designed from the sequences in the fourth and fifth exons
of WRN and were used to amplify the 5' WRN cap
site cDNA from the HeLa cell oligonucleotide-capped cDNA library.
Several PCR products were obtained, and their nucleotide sequences were
determined. As expected, all of the PCR products were found to contain
the 5' untranslated sequence of WRN mRNA. Sequence
determination showed that WRN was transcribed from multiple positions, i.e., positions 1, 3, 4, 6, 11, 12, 31, 56, and 85 (Fig.
1C). Positions 1, 4, and 6 starting with
G seem to be used most frequently as the initiation start sites of
WRN transcription, based both on the results obtained from
S1 nuclease mapping analysis (Fig. 1D) and on the number of clones
obtained after subcloning of the 5' WRN cap site cDNA (data
not shown). Similarly, multiple transcription initiation sites have
recently been found for the human gp130 gene
(28). In this report, we assume that the most upstream start
site is at position +1.

View larger version (57K):
[in this window]
[in a new window]
|
FIG. 1.
WRN promoter region and structures of
plasmids used for promoter assays. (A) Orientation of WRN in
the P1/PAC contig map. Solid lines and numbers represent P1/PAC DNAs
that form the physical map. The approximate positions of WRN
and the STS marker D8S2162 are shown. The transcriptional direction of
WRN is indicated by 5' and 3'. Tel., telomere; Cent.,
centromere. (B) The 2,776-bp DNA fragment generated from PAC 12339 DNA
was placed at the BglII site of the pGL3-Basic vector
upstream of the firefly luciferase gene to form pGL3/A, which was used
as a reporter gene in the promoter assay. A series of WRN-Luc plasmids
containing the sequentially 5'-deleted human WRN (hWRN)
promoter regions (pGL3/B to -R) were prepared from pGL3/A. The
structures of Rb and p53 expression plasmids (pCMV1-Rb, pC53-SN3, and
pC53-249) are shown. CMV, cytomegalovirus. (C) The WRN
transcription start sites are indicated by asterisks. The most upstream
nucleotide position is assumed to be position +1. The
cis-acting Sp1 element binding sites and an RCE motif are
boxed and underlined, respectively. (D) Results of S1 nuclease
protection assay. The ladder (lanes A, C, G, and T) represents the
sequence of pGEM3Zf(+) DNA recognized by the M13 forward primer
(5'-CGCCAGGGTTTTCCCAGTCACGAC-3'), and base 102 is shown by
an arrowhead. Lane 1, S1 mapping with 106 cpm of
32P-labeled probe DNA for K562 cell RNA that contains
WRN mRNA; lane 2, control experiment using yeast tRNA; lane
3, S1 nuclease-undigested 5' 32P-labeled 245-bp DNA
(104 cpm) that encompasses the potential WRN
promoter region from 143 to +102, heat denatured prior to
electrophoresis. The band remaining in the upper part of the gel
indicates the S1 nuclease-resistant duplex DNA formed by annealing of
complementary DNAs during hybridization. The band migrating with base
102 (lane 1) corresponds to the most upstream nucleotide from the
32P-labeled 5' G (from the complementary strand to the
3'-5' CCG indicated by an arrow in panel C) and is designated the +1
position of the WRN mRNA.
|
|
Cloning and nucleotide sequence of the WRN promoter
region.
A physical map containing WRN was made with a
contig of P1/PAC DNAs, and the precise location of WRN was
identified (Fig. 1A). Genomic clones, including the putative promoter
region of WRN, were obtained from the PAC 12339 library by
PCR using primers designed from the sequence of the first exon of
WRN (positions 50 to 154). After the PAC 12339 DNA was
digested with Sau3AI, all resulting fragments were subcloned
into the BamHI site of pBluescript KS(+) (Stratagene). A
PCR-based screening of 100 clones yielded nine independent positive
clones containing 1.4- to 4.0-kb inserts. One of them, clone
pBS/12339-17, containing an insert of about 2.8 kb, was sequenced, and
the analysis confirmed that it contains a 5'-flanking region and the
first exon (Fig. 1C). Figure 1C shows part of this 2.8-kb DNA, a region
corresponding to
85 to +160 that correlates with WRN
promoter activity. The region from positions
85 to
1 contained an
extremely high GC content (80%), whereas the overall GC content of the
entire 2.8-kb fragment was 58%. In addition, multiple copies of
transcription regulatory elements Sp1 (seven), RCE (nine), and AP2
(fourteen) were clustered in the 2.8-kb region. In contrast, no TATA
box or CAAT box was evident. These findings collectively indicated that
the WRN promoter probably is in this region and has promoter characteristics often associated with housekeeping genes.
Analysis of multiple cis elements in the upstream
region of the transcriptional initiation site of WRN.
The
2.8-kb DNA fragment was cloned into the pGL3-Basic vector (WRN-Luc
plasmid). The resulting construct, pGL3/A (
2615~+160), was used for
promoter assays by a luciferase gene placed downstream of the
WRN DNA. To define the region responsible for the
WRN promoter, a series of 5'-deletion mutants of pGL3/A was
constructed (Fig. 2). These deletion
mutants were transfected into HeLa cells, and their promoter activities
were monitored by luciferase production after 48 h of cell
culture. The majority of about 2.5 kb of sequence upstream of the
WRN transcriptional start site was largely dispensable; the
short upstream region from positions
67 to +160 was sufficient (Fig.
2, O). This region contains one RCE motif (RCE-1) and two Sp1 elements
(Sp1-1 and Sp1-2) that are often indispensable as cis-acting
regulatory elements for the constitutive expression of most
housekeeping genes. Several AP2 elements in the upstream region of a
minimal promoter are clearly of little importance to WRN
expression but are required for maximum promoter activity shown by
pGL3/K. Truncation at
57 (pGL3/P), which removes the RCE motif,
decreased the promoter activity by 66% compared with pGL3/O (Fig. 2,
P). Truncation at
35, which left only Sp1-1, largely decreased
luciferase expression and resulted in low promoter activity (Fig. 2,
Q). These results suggest that Sp1-1 may be nonfunctional by itself but
works cooperatively with the other elements at
67 to
36. pGL3/R,
which had no Sp1 element or RCE motif, showed very little promoter
activity (3% compared to pGL3/O) (Fig. 2, R). The promoter activity of
pGL3/O
3', which lacked nucleotides 21 to 160, was about 80% lower
than that of pGL3/O, suggesting the presence of another undefined
fundamental element that cooperates with the essential Sp1-2, Sp1-1,
and RCE sites at
67 to +20. Consequently, the region encompassing
positions
67 to +160 seems to represent the minimal WRN
promoter region required for full activity in the reporter gene assays.

View larger version (19K):
[in this window]
[in a new window]
|
FIG. 2.
Promoter activities detected in the upstream region of
WRN. WRN-Luc plasmids containing various lengths of the
WRN upstream region were transiently transfected into HeLa
cells as described in Materials and Methods. The diagram on the left
shows a map of a series of 5'-truncated WRN promoters in
WRN-Luc plasmids. The 5' ends of the WRN DNA are shown by
nucleotide position numbers from the transcription initiation site.
Open circles, closed circles, and black boxes indicate Sp1, RCE, and
AP2 motifs, respectively. The promoter activities of the 5'-truncated
DNA in WRN-Luc plasmids were measured in HeLa cells and are shown as
luciferase activity on the right. Each value represents the mean
luciferase activity measured in at least three independent experiments.
Bars indicate standard deviations of the mean activities, expressed as
RLU (relative light units) as specified by the manufacturer (EG&G
Bertholdo).
|
|
Effect of the substitution mutation in the Sp1 element on
WRN promoter function.
To examine the contribution of
each Sp1 element to the expression of WRN, we mutated the
Sp1-3, Sp-2, and Sp-1 elements by base substitutions. These changes had
been designed to affect the Sp1 elements, and the mutated WRN-Luc
plasmids (pGL3/S3m, pGL3/S2m,
pGL3/S1m, pGL3/S32m, and
pGL3/S321m) were generated from pGL3/N. They were
transfected into HeLa cells, and their activities were measured. The
single mutation in the Sp1-3, Sp1-2, and Sp1-1 elements had little or
no effect on WRN promoter activity (Fig.
3, S3m, S2m, and S1m). A triple mutation
of all three Sp1 elements resulted in about 90% reduction of promoter
activity, leaving a low level of activity, but 3-fold higher activity
than for pGL3/R, which lacked Sp1-3, Sp-2, and Sp-1 (Fig. 3,
S321m and R
3). The promoter activity in pGL3/Q was
severely reduced, to 20% of that of pGL3/N, upon removal of the Sp1-3
and Sp1-2 elements. By contrast, the double mutations in Sp1-3 and Sp-2 restored 60% of its activity (Fig. 3, Q
35 and S32m).
These results strongly suggest that some element(s) other than Sp1
elements in the
85 to
36 region activates the WRN
promoter. These findings are consistent with the data obtained for the
5'-deletion experiments and support the hypothesis that the Sp1
elements upregulate WRN transcription. In addition, another
response element(s) in the WRN promoter region, such as the
RCE motif GGTGGG at
64 to
59, cooperates with the Sp1
elements (see below).

View larger version (22K):
[in this window]
[in a new window]
|
FIG. 3.
Effects of the 5'-deletion and base-substitution
mutations in the cis-regulatory Sp1 elements and RCE on
WRN promoter activity. WRN-Luc plasmids containing various
base-substitution mutations in three Sp1 elements and an RCE motif were
generated. Their promoter activities were measured by transfection into
HeLa cells and compared with the promoter activity of pGL3/N to -R. The
diagram on the left shows the structure of each of the 5'-deletion and
base-substitution mutants of the WRN promoter; the
substituted bases are represented by lowercase boldface letters.
Promoter activities in the modified WRN promoter region are
shown as luciferase activity on the right. Each value represents the
mean activity of luciferase detected in at least three independent
experiments. Bars indicate standard deviations of the mean activities,
expressed as RLU (relative light units) as specified by the
manufacturer (EG&G Bertholdo).
|
|
Effect of the RCE motif on WRN promoter activity.
To confirm that the RCE (positions
64 to
59) in the WRN
promoter region participates in WRN expression, we
constructed a series of WRN-Luc plasmids containing a modified
WRN promoter with a substitution mutation in the RCE motif
(pGL3/S3m/Rm, pGL3/S32m/Rm, pGL3/S321m/Rm, and pGL3/Rm). In this study, mutation of the
RCE motif in pGL3/Rm showed no effect on promoter activity compared to
that of pGL3/N (Fig. 3, Rm). However, the activity of
pGL3/S3m/Rm was rendered lower than that of
pGL3/S3m and was almost the same as that of pGL3/P, which
lacked the Sp1-3 element and RCE motif (Fig. 3, S3m/Rm,
S3m, and P). The mutation of the RCE motif in pGL3/S32m/Rm reduced its promoter activity to lower than
that of pGL3/S32m and to a level equivalent to that of
pGL3/Q, which lacked the Sp1-3, Sp1-2, and RCE motifs (Fig. 3,
S32m/Rm, S32m, and Q). Very little promoter
activity remained in pGL3/S321m/Rm, which has mutations in
all four elements, and this level of activity was the same as for
pGL3/R, with all four elements deleted (Fig. 3, S321m/Rm
and R). These findings suggest that the WRN promoter was
upregulated not only by the Sp1 element but also by the RCE motif.
Nuclear proteins that bind to the promoter region of
WRN.
To examine if the Sp1 elements and RCE motif indeed
bind to the corresponding nuclear protein factor, we performed
EMSAs with HeLa cell nuclear extract. First, EMSAs were done with
three double-stranded oligonucleotide probes containing the Sp1-3,
Sp1-2, or Sp1-1 element in the WRN promoter region. We
observed four DNA-protein complexes (complexes I to IV [Fig.
4A]) when we used Sp1-3 and Sp1-2 as probes (Fig. 4, lanes 1 and 6), while complex I was not detected with
Sp1-1 alone (lane 11). Complex formation was inhibited specifically by
adding a 50-fold excess of unlabeled Sp1 consensus oligonucleotide (lanes 2, 7, and 12) but not by the AP1 oligonucleotide (lanes 3, 8, and 13), indicating that these DNA-protein complexes were formed by
some Sp1-specific binding protein(s) and the Sp1 oligonucleotide. Indeed, in subsequent supershift analysis using a human Sp1-specific polyclonal antibody, antibody addition further decreased the mobility of the majority of these DNA-protein complexes (lanes 4, 9, and 14),
while the nonimmunized rabbit IgG added to the binding reaction mixtures as a control did not affect the EMSA profiles (lanes 5, 10, and 15). When the efficiency of complex formation with Sp1 proteins was
compared among the probe oligonucleotides, the Sp1 protein showed an
increasing order of Sp1-3 > Sp1-2 > Sp1-1, suggesting that
the adjacent sequences of Sp1 elements, and perhaps the intervening RCE
motif (and included in Sp1-3 and Sp1-2 probes), stimulate complex
formation. In any event, these data confirmed that the cellular Sp1
protein can bind specifically to these Sp1 elements, with some
differences in binding efficiency. We also noted minor complexes but
clearly of another type because their migration profiles were not
affected by the Sp1-specific antibody (lanes 4, 9, and 14). These
protein complexes were apparently specific in binding to the Sp1
element but may have included proteins other than the known Sp1
protein.

View larger version (66K):
[in this window]
[in a new window]
|
FIG. 4.
Characterization of the nuclear protein that interacts
with oligonucleotides containing Sp1 elements and an RCE motif. Nuclear
extracts from HeLa cells (2 to 5 µg of protein) were incubated with
the 32P-labeled double-stranded oligonucleotide probes that
contained WRN Sp1-3 (positions from 86 to 57) (A), Sp1-2
(positions from 65 to 36) (B), Sp1-1 (positions from 46 to 17)
(C), and RCE-1 (positions from 70 to 51) (D) in the absence (lanes
1, 6, 11, and 16) or presence (lanes 2, 7, 12, and 17) of 50-fold molar
excess amounts of unlabeled Sp1 oligonucleotides. The mixtures were
electrophoresed in a 4% polyacrylamide gel as described in Materials
and Methods. Similar experiments were also done with 50-fold excess
amounts of unlabeled AP1 oligonucleotide (lanes 3, 8, 13, and 18). In
the experiments represented by lanes 4, 9, 14, and 19, the Sp1
protein-specific rabbit IgG antibodies (5 µg) were included in the
reaction mixtures before incubation; as the control for these
experiments, the same reactions were performed with nonimmunized rabbit
IgG fraction (5 µg) (lanes 5, 10, 15, and 20).
|
|
Udvadia et al. (44) reported that transcriptional regulation
of the c-fos gene by RCE is mediated by (i) the Sp1 protein binding to the RCE motif and regulating promoter activity and (ii) the
Rb protein activating the RCE-dependent transcription through Sp1. To
confirm the binding of the Sp1 protein to the RCE motif in the
WRN promoter region, similar EMSAs were performed with a
double-stranded oligonucleotide probe containing the RCE motif. Three
DNA-protein complexes, II, III, and IV, were detected (Fig. 4, lane
16). The unlabeled Sp1 consensus oligonucleotide, but not AP1
oligonucleotide, inhibited the formation of these DNA-protein complexes
(lanes 17 and 18). A human Sp1-specific polyclonal antibody added to
the binding reaction mixture decreased the mobility of these
DNA-protein complexes in the supershift analysis (lane 19). Addition of
nonimmunized rabbit IgG had no effect on the mobility of these
complexes (lane 20), indicating that the complex formation is Sp1
specific. The same results were obtained when we performed EMSAs with
purified human Sp1 protein (data not shown). These data indicated that
the Sp1 protein binds to the RCE motif in the WRN promoter
region as was reported by Udvadia et al. (44).
The WRN promoter is upregulated by Rb and downregulated
by p53.
To examine the effects of the Rb protein on WRN
promoter activity, we used Saos2 cells lacking the active Rb and p53
proteins (18). First, we cotransfected the Saos2 cells with
the WRN-Luc plasmid pGL3/A and increasing amounts of the Rb expression
plasmid (pCMV1-Rb) and measured luciferase activities. Strikingly,
cotransfection with the Rb expression plasmids resulted in a
significant stimulation (maximum of 2.5-fold) of WRN
promoter activity in a plasmid dose-dependent manner (Fig.
5A). The production of Rb was confirmed
by Western blot analysis using lysates of cells transfected with the Rb
expression plasmid (data not shown). To confirm that the RCE motif or
Sp1 elements indeed contributed to the Rb-mediated upregulation, we cotransfected WRN-Luc plasmids (pGL3/A to -R) with pCMV1-Rb (1 µg)
and measured promoter activities. WRN promoter activities in
pGL3/A to -O were increased by the Rb protein about twofold (Fig. 5B),
but this stimulatory effect did not occur in pGL3/P to -R, which lacked
the RCE motif (Fig. 5B). These results suggest that Rb protein
upregulates WRN expression and that the region from
67 to
57 was essential for this effect. Consistent with these results, a
series of promoter assays with various WRN-Luc plasmids
(pGL3/S3m, -S3m/Rm, -S321m/Rm, and
-Rm) containing substitution mutations showed that the stimulation by
Rb is pronounced when the RCE motif is intact, while the overall
promoter activity appears to depend on the number of intact Sp1
elements in this
78 to
21 region (Table
1).

View larger version (15K):
[in this window]
[in a new window]
|
FIG. 5.
Regulatory effects of Rb protein on WRN
promoter activity in Saos2 cells. (A) pGL3/A, a WRN-Luc plasmid
containing the full-length WRN promoter region, was
cotransfected with increasing amounts of pCMV1-Rb into Saos2 cells,
which are known to be deficient in active Rb and p53. The activity of
the WRN promoter in the transfected cells was determined and
compared with the activity of pGL3/A alone. The values represent
relative activities of pGL3/A expressed in the presence of Rb, assuming
the luciferase activity with pGL3/A alone to be 1.0. The data were
reproducible in two independent experiments. (B) WRN-Luc plasmids
(pGL3/A to -R) containing various lengths of the WRN
promoter region were cotransfected with Rb-expressing pCMV1-Rb (1 µg)
in Saos2 cells, and the site of the WRN promoter that
responds to Rb was investigated. Gray columns show WRN
promoter activities associated with pGL3/A to -R alone; black columns
show WRN promoter activities obtained in the presence of Rb.
The data were reproducible in two independent experiments. Luciferase
activity is expressed as RLU (relative light units) as specified by the
manufacturer (EG&G Bertholdo).
|
|
View this table:
[in this window]
[in a new window]
|
TABLE 1.
Transcriptional activity of mutated WRN
promoter cotransfected with Rb and p53 expression plasmids in
Saos2 cellsa
|
|
Next, we studied the effect of p53 on WRN promoter activity
because p53 protein often participates in transcriptional suppression of the Rb gene and the genes that contain Sp1 elements (4, 35,
46). In cotransfection experiments in which increasing amounts of
p53 expression plasmid (pC53-SN3) were expressed in Saos2 cells,
WRN promoter activity of pGL3/A was downregulated a maximum
of 90% (Fig. 6A, closed circle). By
contrast, the inactive p53 mutant protein containing a single amino
acid substitution at position 249 (43) failed to show this
downregulation (Fig. 6A). Again, the production of p53 in the
transfected Saos2 cells was confirmed for two different types of p53 by
Western blot analysis using cell lysates (data not shown). To clarify
further the cis-regulatory element involved in the
p53-mediated downregulation, WRN-Luc plasmids pGL3/A to -R were
cotransfected with pC53-SN3 (0.1 µg), and promoter activities were
measured (Fig. 6B). Here, the original WRN promoter activities were reduced to about 50% by the presence of p53 protein, regardless of the modifications of WRN promoter elements
tested. Unlike the effect of Rb, the suppression of promoter activity by p53 was not affected by alterations in the transcriptional elements
in the WRN promoter (Table 1). Downstream deletion at 21 to
160, in addition to mutations in Sp1-3, -2, and -1 and the RCE,
however, prevented repression by the overexpressed p53 (data not
shown). The mechanism behind this transcriptional suppression may be
accounted for by the finding by Borellini and Glazer (4) that the Sp1 protein was prevented from binding to the promoter region
by a p53-Sp1 protein complex. Similar types of modulations by Rb or p53
were observed when HeLa cells were cotransfected with WRN-Luc plasmids
and the Rb or p53 expression plasmid (data not shown), although the
levels of modulation were less pronounced, perhaps due to endogenous Rb
and p53 in the HeLa cells. As expected, overexpression of either Rb or
p53 did not affect the morphology or proliferation of transfected Saos2
cells, as analyzed by microscopy and cell counting.

View larger version (17K):
[in this window]
[in a new window]
|
FIG. 6.
Regulatory effects of p53 protein on WRN
promoter activity in Saos2 cells. (A) pGL3/A, a WRN-Luc plasmid
containing the full-length WRN promoter region, was
cotransfected with increasing amounts of pC53-SN3 (closed circles) or
pC53-249 (open circles) into Saos2 cells, which are known to be
deficient in active Rb and p53. The activity of the WRN
promoter in the transfected cells was determined and compared with the
activity of pGL3/A alone. The values represent relative activities of
pGL3/A expressed in the presence of p53, assuming the luciferase
activity with pGL3/A alone to be 1.0. The data were reproducible in two
independent experiments. (B) WRN-Luc plasmids (pGL3/A to -R) containing
various lengths of the WRN promoter region were
cotransfected with p53 expressing pC53-SN3 (0.1 µg) in Saos2 cells,
and the site of the WRN promoter that responds to p53 was
investigated. Gray columns show WRN promoter activities
associated with pGL3/A to -R alone; white columns show WRN
promoter activities obtained in the presence of p53. The data were
reproducible in two independent experiments. Luciferase activity is
expressed as RLU (relative light units) as specified by the
manufacturer (EG&G Bertholdo).
|
|
Effects of Rb and p53 on the endogenous WRN mRNA
expression level.
To determine whether the endogenous
WRN mRNA level in Saos2 cells is indeed modulated by Rb and
p53, we compared the WRN mRNA levels of SRb-7 and Sp53-3
cells by Northern blot analysis in the presence or absence of
overexpressed Rb and p53. The level of WRN mRNA in the
Rb-overexpressing SRb-7 cells was fourfold higher than that in
Rb-nonexpressing cells (Fig. 7, lanes 1 and 2). By contrast, the level of WRN mRNA in the
p53-overexpressing Sp53-3 cells was less than 50% of that of
p53-nonexpressing cells (lanes 3 and 4). These results indicated that
Rb and p53 indeed modulate the WRN gene expression.

View larger version (56K):
[in this window]
[in a new window]
|
FIG. 7.
Northern blot analysis of SRb-7 and Sp53-3 cells
carrying the tetracycline-inducible Rb and p53 expression plasmids.
SRb-7 (A) or Sp53-3 (B) cells were cultured in the presence or absence
of 1 µg of tetracycline (Tc) per ml at 37°C for 6 or 12 h,
respectively, poly(A)+ RNA was extracted, and Northern blot
analysis was performed with a 32P-radiolabeled probe
prepared from the C-terminal region, which includes the 3' untranslated
region of the WRN gene. The relative intensities of
individual WRN mRNA bands were estimated with a BAS-1500
Bioimaging Analyzer (Fujifilm).
|
|
 |
DISCUSSION |
WRN promoter and Sp1-mediated transcription.
Although much progress has been made in determining the genomic
structure of WRN, the types of WRN mutations occurring in patients with WS, and the biochemical nature of the DNA helicase gene
product, little is known about how WRN expression is
regulated and the nature of the cis element(s) and
trans-activating factor(s) involved. In this study, we
answered some of these questions. First, we analyzed about 2.8 kb of
the upstream region of WRN and found that the transcription
start site, i.e., the capping site of WRN mRNA, was multiple
but that the main sites were the +1, +4, and +6 positions (Fig. 1C). S1
mapping experiments with mRNAs from human K562 cells that express a
relatively high level of WRN transcripts supported these
findings (Fig. 1D). Proximal to this transcription initiation site
cluster, we found two Sp1 elements and one RCE cis-acting
motif within the minimal WRN promoter region (positions
67
to +160), required for full activity in a reporter gene assay.
Additional elements, including 5 Sp1, 8 RCE, and 14 AP2 motifs, are
distributed throughout the upstream 1.4 kb (Fig. 2). Since the Sp1
element is conserved in the promoters of most housekeeping genes,
WRN seems to be a housekeeping gene. Consistent with this
view, there is neither a TATA box nor a CAAT box proximal to this
transcription initiation site. The Sp1 protein that binds to the
consensus Sp1 element GGCGGG is also capable of binding to
the RCE motif GGTGGG and exerts a stimulatory effect on the
transcription (Fig. 4D and reference 44). Perhaps,
as reported by Mastrangelo et al. (24), these Sp1 and the
Sp1-like elements cooperate in the Sp1-mediated transcription and
regulate WRN housekeeping expression.
Upregulation of the WRN promoter by Rb.
A DNA
binding assay and a mutational analysis for the WRN promoter
region by using a reporter gene assay (Fig. 3 and 4) collectively indicated that WRN expression is directed mainly by the Sp1
elements and cellular Sp1 proteins. The RCE motif in the promoter
appeared to have cooperative roles with Sp1 elements, and together they showed maximum promoter activity in Saos2 cells when the Rb protein was
overexpressed (Fig. 5 and Table 1). With respect to this stimulatory
effect of Rb, Chen et al. (6) reported that the Rb protein
upregulates Sp1-mediated gene expression not by directly binding to the
Sp1 element or to the Sp1 protein but by binding to the 20-kDa Sp1-I
protein, a negative regulator of the Sp1 protein, thus liberating
active Sp1 transcription factors from the inactive Sp1-I-Sp1 complex.
Thus, the overexpressed Rb protein in Saos2 cells might have activated
the WRN promoter by activating the Sp1 proteins that bind to
the Sp1 elements and the RCE motifs abundant in the WRN
promoter region.
Downregulation of the WRN promoter by p53.
In
contrast to the upregulation of the WRN promoter by Rb, the
overexpression of wild-type p53, but not of mutant p53, downregulated the WRN promoter activity concentration dependently (Fig.
6A). Wild-type p53 downregulates several genes containing a TATA box by
forming a complex with the TATA-binding protein (11).
However, this may not be the case for the WRN promoter,
which does not contain a TATA box. Rather, this inhibitory effect of
the overexpressed p53 is explained by the finding of Borellini et al.
(4) that increased levels of p53 resulted in complexes with
Sp1 protein, rendering the Sp1 protein inactive for Sp1-mediated
transcription. Similarly, the overexpressed p53 in Saos2 cells might
have inhibited dose dependently the trans-activating
activity of Sp1 by a protein-protein interaction, resulting in negative
regulation of the WRN promoter.
Modulation of Sp1-mediated WRN expression by Rb and
p53.
The overexpressed Rb and p53 proteins also affected the
endogenous WRN mRNA levels in Saos2 cells, consistent with
the results obtained for the cotransfection experiments shown in Fig.
7. What is the biological significance of these two ways of regulating WRN expression by Rb and p53? The WRN DNA
helicase is a nuclear enzyme nonessential for life and development but
important for the suppression of hyperrecombination and genomic
instability (16). Its presence prevented normal individuals
from the onset of premature aging phenotypes. Although the levels of
intact WRN mRNA in the heterozygotes of parents and the
relatives of patients carrying a deficient allele are low, they are
apparently sufficient (47). Thus, maintaining WRN
mRNA over a certain threshold level may be very important for cell
homeostasis and for the concentration of WRN helicase during
the cell cycle. While the biological function(s) of the WRN
helicase remains to be clarified, we speculate that the basal level of
WRN expression governed by Sp1-mediated regulation may be
further modulated positively by Rb and negatively by p53 in association
with various cellular events including the cell cycle, DNA damage, and
cell senescence. In this context, Wang et al. (45) reported
that p53 inhibits expression of human topoisomerase II
, another
nuclear enzyme involved in DNA metabolism, dose dependently through the
inverted CCAAT element in the promoter region. Therefore, a plausible
speculation is that the simultaneous downregulation of two important
enzymes involved in DNA metabolism by p53 may result in an augmented
illegitimate hyperrecombination and/or genomic instability, which are
both associated with WS.
WRN expression in WS and natural senescence.
In WS
patient cells, overall WRN expression is perturbed
completely due to the impaired nuclear import of deficient protein products (26). This perturbation in expression, which would occur even in the case of transcription modulation by Rb and p53, is
the primary cause of the generation of premature aging phenotypes in
patients at an early stage of life. How, then, does the modulation by
Rb and p53 affect WRN expression in the course of natural
aging, and what is its relation to the onset of the aging phenotype at a later period of life? This is not clear for Rb. However, Kulju and
Lehman (22) reported that the steady-state level of p53 protein increases in the near-senescent human diploid fibroblast cells;
also, Sugrue et al. (39) found that the overexpression of
wild-type p53 in human EJ cells triggers a rapid onset of
G1 and G2/M growth arrest, which is
irreversible and results in senescence phenotypes, suggesting a link
with p53. These data imply that p53 has important roles in cell
senescence, while the role of Rb in the induction of senescence cannot
be ruled out (34). Both the defective expression in WS
patients and the expression modulated by Rb (upregulation) and by p53
(downregulation) in Saos2 cells prompt us to hypothesize that a
potential gradual suppression of WRN expression may occur
with natural senescence, accounting for an increased frequency of
genetic instability in the senescent cells. Further studies are needed
to determine if natural aging, unlike aging of WS patient cells, is
associated with a gradual reduction in WRN expression that
is regulated by p53 and Rb or by other transcription factors that
interact directly or indirectly with the WRN promoter.
 |
ACKNOWLEDGMENTS |
This work was supported by the Organization for Drug ADR Relief,
R & D Promotion and Product Review, of the Japanese Government.
We thank Masanobu Sugimoto (AGENE Research Institute) for valuable
discussion.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: AGENE Research
Institute, 200 Kajiwara, Kamakura, Kanagawa 247, Japan. Phone:
81-467-46-9590. Fax: 81-467-48-6595. E-mail:
furuichi{at}agene.co.jp.
 |
REFERENCES |
| 1.
|
Agoff, S. N.,
J. Hou,
D. I. Linzer, and B. Wu.
1993.
Regulation of the human hsp70 promoter by p53.
Science
259:84-87[Abstract/Free Full Text].
|
| 2.
|
Altschul, S. F.,
W. Gish,
W. Miller,
E. W. Myers, and D. J. Lipman.
1990.
Basic local alignment search tool.
J. Mol. Biol.
215:403-410[Medline].
|
| 3.
|
Berk, A. J., and P. A. Sharp.
1977.
Sizing and mapping of early adenovirus mRNAs by gel electrophoresis of S1 endonuclease-digested hybrids.
Cell
12:721-732[Medline].
|
| 4.
|
Borellini, F., and R. I. Glazer.
1993.
Induction of Sp1-p53 DNA-binding heterocomplexes during granulocyte/macrophage colony-stimulating factor-dependent proliferation in human erythroleukemia cell line TF-1.
J. Biol. Chem.
268:7923-7928[Abstract/Free Full Text].
|
| 5.
|
Chellappan, S. P.,
S. Hiebert,
M. Mudryj,
J. M. Horowitz, and J. R. Nevins.
1991.
The E2F transcription factor is a cellular target for the RB protein.
Cell
65:1053-1061[Medline].
|
| 6.
|
Chen, L. I.,
T. Nishinaka,
K. Kwan,
I. Kitabayashi,
K. Yokoyama,
Y. H. Fu,
S. Grunwald, and R. Chiu.
1994.
The retinoblastoma gene product RB stimulates Sp1-mediated transcription by liberating Sp1 from a negative regulator.
Mol. Cell. Biol.
14:4380-4389[Abstract/Free Full Text].
|
| 7.
|
Chomczynski, P., and N. Sacchi.
1987.
Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction.
Anal. Biochem.
162:156-159[Medline].
|
| 8.
|
Dignam, J. D.,
R. M. Lebovitz, and R. G. Roeder.
1983.
Accurate transcription initiation by RNA polymerase II in a soluble extract from isolated mammalian nuclei.
Nucleic Acids Res.
11:1475-1489[Abstract/Free Full Text].
|
| 9.
|
Epstein, C. J.,
G. M. Martin,
A. L. Schultz, and A. G. Motulsky.
1966.
Werner's syndrome a review of its symptomatology, natural history, pathologic features, genetics and relationship to the natural aging process.
Medicine (Baltimore)
45:177-221[Medline].
|
| 10.
|
Faragher, R. G.,
I. R. Kill,
J. A. Hunter,
F. M. Pope,
C. Tannock, and S. Shall.
1993.
The gene responsible for Werner syndrome may be a cell division "counting" gene.
Proc. Natl. Acad. Sci. USA
90:12030-12034[Abstract/Free Full Text].
|
| 11.
|
Farmer, G.,
J. Colgan,
Y. Nakatani,
J. L. Manley, and C. Prives.
1996.
Functional interaction between p53, the TATA-binding protein (TBP), and TBP-associated factors in vivo.
Mol. Cell. Biol.
16:4295-4304[Abstract].
|
| 12.
|
Felgner, P. L.,
T. R. Gadek,
M. Holm,
R. Roman,
H. W. Chan,
M. Wenz,
J. P. Northrop,
G. M. Ringold, and M. Danielsen.
1987.
Lipofection: a highly efficient, lipid-mediated DNA-transfection procedure.
Proc. Natl. Acad. Sci. USA
84:7413-7417[Abstract/Free Full Text].
|
| 13.
|
Goto, M.,
O. Imamura,
J. Kuromitsu,
T. Matsumoto,
Y. Yamabe,
Y. Tokutake,
N. Suzuki,
B. Mason,
D. Drayna,
M. Sugawara,
M. Sugimoto, and Y. Furuichi.
1997.
Analysis of helicase gene mutations in Japanese Werner's syndrome patients.
Hum. Genet.
99:191-193[Medline].
|
| 14.
|
Goto, M.,
R. W. Miller,
Y. Ishikawa, and H. Sugano.
1996.
Excess of rare cancers in Werner syndrome (adult progeria).
Cancer Epidemiol. Biomarkers Prev.
5:239-246[Abstract].
|
| 15.
|
Goto, M.,
K. Tanimoto,
Y. Horiuchi, and T. Sasazuki.
1981.
Family analysis of Werner's syndrome: a survey of 42 Japanese families with a review of the literature.
Clin. Genet.
19:8-15[Medline].
|
| 16.
|
Guarente, L.
1996.
Do changes in chromosomes cause aging?
Cell
86:9-12[Medline].
|
| 17.
|
Haffner, R., and M. Oren.
1995.
Biochemical properties and biological effects of p53.
Curr. Opin. Genet. Dev.
5:84-90[Medline].
|
| 18.
|
Kaghad, M.,
H. Bonnet,
A. Yang,
L. Creancier,
J.-C. Biscan,
A. Valent,
A. Minty,
P. Chalon,
J.-M. Lelias,
X. Dumont,
P. Ferrara,
F. McKeon, and D. Caput.
1997.
Monoallelically expressed gene related to p53 at 1p36, a region frequently deleted in neuroblastoma and other human cancers.
Cell
90:809-819[Medline].
|
| 19.
|
Kim, S. J.,
H. D. Lee,
P. D. Robbins,
K. Busam,
M. B. Sporn, and A. B. Roberts.
1991.
Regulation of transforming growth factor beta 1 gene expression by the product of the retinoblastoma-susceptibility gene.
Proc. Natl. Acad. Sci. USA
88:3052-3056[Abstract/Free Full Text].
|
| 20.
|
Kim, S. J.,
S. Wagner,
F. Liu,
M. A. O'Reilly,
P. D. Robbins, and M. R. Green.
1992.
Retinoblastoma gene product activates expression of the human TGF-beta 2 gene through transcription factor ATF-2.
Nature
358:331-334[Medline].
|
| 21.
|
Kley, N.,
R. Y. Chung,
S. Fay,
J. P. Loeffler, and B. R. Seizinger.
1992.
Repression of the basal c-fos promoter by wild-type p53.
Nucleic Acids Res.
20:4083-4087[Abstract/Free Full Text].
|
| 22.
|
Kulju, K. S., and J. M. Lehman.
1995.
Increased p53 protein associated with aging in human diploid fibroblasts.
Exp. Cell Res.
217:336-345[Medline].
|
| 23.
|
Martin, G. M.
1978.
Genetic syndromes in man with potential relevance to the pathobiology of aging.
Birth Defects
14:5-39.
|
| 24.
|
Mastrangelo, I. A.,
A. J. Courey,
J. S. Wall,
S. P. Jackson, and P. V. Hough.
1991.
DNA looping and Sp1 multimer links: a mechanism for transcriptional synergism and enhancement.
Proc. Natl. Acad. Sci. USA
88:5670-5674[Abstract/Free Full Text].
|
| 25.
|
Matsumoto, T.,
O. Imamura,
Y. Yamabe,
J. Kuromitsu,
Y. Tokutake,
A. Shimamoto,
N. Suzuki,
M. Satoh,
S. Kitao,
K. Ichikawa,
H. Kataoka,
K. Sugawara,
W. Thomas,
B. Mason,
Z. Tsuchihashi,
D. Drayna,
M. Sugawara,
M. Sugimoto,
Y. Furuichi, and M. Goto.
1997.
Mutation and haplotype analyses of the Werner's syndrome gene based on its genomic structure: genetic epidemiology in the Japanese population.
Hum. Genet.
100:123-130[Medline].
|
| 26.
|
Matsumoto, T.,
A. Shimamoto,
M. Goto, and Y. Furuichi.
1997.
Impaired nuclear localization of defective DNA helicases in Werner's syndrome.
Nat. Genet.
16:335-336[Medline].
|
| 27.
|
Monnat, R. J., Jr.
1992.
Werner syndrome: molecular genetics and mechanistic hypotheses.
Exp. Gerontol.
27:447-453[Medline].
|
| 28.
|
O'Brien, C. A., and S. C. Manolagas.
1997.
Isolation and characterization of the human gp130 promoter. Regulation by STATS.
J. Biol. Chem.
272:15003-15010[Abstract/Free Full Text].
|
| 29.
|
Ookawa, K.,
S. Tsuchida,
J. Adachi, and J. Yokota.
1997.
Differentiation induced by RB expression and apoptosis induced by p53 expression in an osteosarcoma cell line.
Oncogene
14:1389-1396[Medline].
|
| 30.
|
Robbins, P. D.,
J. M. Horowitz, and R. C. Mulligan.
1990.
Negative regulation of human c-fos expression by the retinoblastoma gene product.
Nature
346:668-671[Medline].
|
| 31.
|
Runger, T. M.,
C. Bauer,
B. Dekant,
K. Moller,
P. Sobotta,
C. Czerny,
M. Poot, and G. M. Martin.
1994.
Hypermutable ligation of plasmid DNA ends in cells from patients with Werner syndrome.
J. Invest. Dermatol.
102:45-48[Medline].
|
| 32.
|
Salk, D.,
E. Bryant,
H. Hoehn,
P. Johnston, and G. M. Martin.
1985.
Growth characteristics of Werner syndrome cells in vitro.
Adv. Exp. Med. Biol.
190:305-311[Medline].
|
| 33.
|
Schonberg, S.,
M. F. Niermeijer,
D. Bootsma,
E. Henderson, and J. German.
1984.
Werner's syndrome: proliferation in vitro of clones of cells bearing chromosome translocations.
Am. J. Hum. Genet.
36:387-397[Medline].
|
| 34.
|
Shay, J. W.,
O. M. Pereira-Smith, and W. E. Wright.
1991.
A role for both RB and p53 in the regulation of human cellular senescence.
Exp. Cell Res.
196:33-39[Medline].
|
| 35.
|
Shiio, Y.,
T. Yamamoto, and N. Yamaguchi.
1992.
Negative regulation of Rb expression by the p53 gene product.
Proc. Natl. Acad. Sci. USA
89:5206-5210[Abstract/Free Full Text].
|
| 36.
|
Shimamoto, A.,
S. Kitao,
K. Ichikawa,
N. Suzuki,
Y. Yamabe,
O. Imamura,
Y. Tokutake,
M. Satoh,
T. Matsumoto,
J. Kuromitsu,
H. Kataoka,
K. Sugawara,
M. Sugawara,
M. Sugimoto,
M. Goto, and Y. Furuichi.
1996.
A unique human gene that spans over 230 kb in the human chromosome 8p11-12 and codes multiple family proteins sharing RNA-binding motifs.
Proc. Natl. Acad. Sci. USA
93:10913-10917[Abstract/Free Full Text].
|
| 37.
|
Singh, H.,
R. Sen,
D. Baltimore, and P. A. Sharp.
1986.
A nuclear factor that binds to a conserved sequence motif in transcriptional control elements of immunoglobulin genes.
Nature
319:154-158[Medline].
|
| 38.
|
Smoller, D. A.,
D. Petrov, and D. L. Hartl.
1991.
Characterization of bacteriophage P1 library containing inserts of Drosophila DNA of 75-100 kilobase pairs.
Chromosoma
100:487-494[Medline].
|
| 39.
|
Sugrue, M. M.,
D. Y. Shin,
S. W. Lee, and S. A. Aaronson.
1997.
Wild-type p53 triggers a rapid senescence program in human tumor cells lacking functional p53.
Proc. Natl. Acad. Sci. USA
94:9648-9653[Abstract/Free Full Text].
|
| 40.
|
Suzuki, N.,
A. Shimamoto,
O. Imamura,
J. Kuromitsu,
S. Kitao,
M. Goto, and Y. Furuichi.
1997.
DNA helicase activity in Werner's syndrome gene product synthesized in a baculovirus system.
Nucleic Acids Res.
25:2973-2979[Abstract/Free Full Text].
|
| 41.
|
Tahara, H.,
Y. Tokutake,
S. Maeda,
H. Kataoka,
T. Watanabe,
M. Satoh,
T. Matsumoto,
M. Sugawara,
T. Ide,
M. Goto,
Y. Furuichi, and M. Sugimoto.
1997.
Abnormal telomere dynamics of B-lymphoblastoid cell strains from Werner's syndrome patients transformed by Epstein-Barr virus.
Oncogene
15:1911-1920[Medline].
|
| 42.
|
Tuteja, N., and R. Tuteja.
1996.
DNA helicases: the long unwinding road.
Nat. Genet.
13:11-12[Medline].
|
| 43.
|
Uchida, T.,
K. Takahashi,
K. Tatsuno,
U. Dhingra, and J. F. Eliason.
1996.
Inhibition of hepatitis-B-virus core promoter by p53: implications for carcinogenesis in hepatocytes.
Int. J. Cancer
67:892-897[Medline].
|
| 44.
|
Udvadia, A. J.,
K. T. Rogers,
P. D. Higgins,
Y. Murata,
K. H. Martin,
P. A. Humphrey, and J. M. Horowitz.
1993.
Sp-1 binds promoter elements regulated by the RB protein and Sp-1-mediated transcription is stimulated by RB.
Proc. Natl. Acad. Sci. USA
90:3265-3269[Abstract/Free Full Text].
|
| 45.
|
Wang, Q.,
G. P. Zambetti, and D. P. Suttle.
1997.
Inhibition of DNA topoisomerase II alpha gene expression by the p53 tumor suppressor.
Mol. Cell. Biol.
17:389-397[Abstract].
|
| 46.
|
Webster, N. J.,
J. L. Resnik,
D. B. Reichart,
B. Strauss,
M. Haas, and B. L. Seely.
1996.
Repression of the insulin receptor promoter by the tumor suppressor gene product p53: a possible mechanism for receptor overexpression in breast cancer.
Cancer Res.
56:2781-2788[Abstract/Free Full Text].
|
| 47.
|
Yamabe, Y.,
M. Sugimoto,
M. Satoh,
N. Suzuki,
M. Sugawara,
M. Goto, and Y. Furuichi.
1997.
Down-regulation of the defective transcripts of the Werner's syndrome gene in the cells of patients.
Biochem. Biophys. Res. Commun.
236:151-154[Medline].
|
| 48.
|
Yu, C. E.,
J. Oshima,
Y. H. Fu,
E. M. Wijsman,
F. Hisama,
R. Alisch,
S. Matthews,
J. Nakura,
T. Miki,
S. Ouais,
G. M. Martin,
J. Mulligan, and G. D. Schellenberg.
1996.
Positional cloning of the Werner's syndrome gene.
Science
272:258-262[Abstract].
|
| 49.
|
Yu, C. E.,
J. Oshima,
E. M. Wijsman,
J. Nakura,
T. Miki,
C. Piussan,
S. Matthews,
Y. H. Fu,
J. Mulligan,
G. M. Martin, and G. D. Schellenberg.
1997.
Mutations in the consensus helicase domains of the Werner syndrome gene. Werner's Syndrome Collaborative Group.
Am. J. Hum. Genet.
60:330-341[Medline].
|
Molecular and Cellular Biology, November 1998, p. 6191-6200, Vol. 18, No. 11
0270-7306/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Zhang, Q., Liu, Y., Zhou, J., Chen, W., Zhang, Y., Liber, H. L.
(2007). Wild-type p53 reduces radiation hypermutability in p53-mutated human lymphoblast cells. Mutagenesis
22: 329-334
[Abstract]
[Full Text]
-
Ku, T. K.S., Nguyen, D. C., Karaman, M., Gill, P., Hacia, J. G., Crowe, D. L.
(2007). Loss of p53 Expression Correlates with Metastatic Phenotype and Transcriptional Profile in a New Mouse Model of Head and Neck Cancer. Mol Cancer Res
5: 351-362
[Abstract]
[Full Text]
-
Zhang, Y., Liao, M., Dufau, M. L.
(2006). Phosphatidylinositol 3-Kinase/Protein Kinase C{zeta}-Induced Phosphorylation of Sp1 and p107 Repressor Release Have a Critical Role in Histone Deacetylase Inhibitor-Mediated Depression of Transcription of the Luteinizing Hormone Receptor Gene.. Mol. Cell. Biol.
26: 6748-6761
[Abstract]
[Full Text]
-
Dhar, S. K., Xu, Y., Chen, Y., Clair, D. K. St.
(2006). Specificity Protein 1-dependent p53-mediated Suppression of Human Manganese Superoxide Dismutase Gene Expression. J. Biol. Chem.
281: 21698-21709
[Abstract]
[Full Text]
-
Sommers, J. A., Sharma, S., Doherty, K. M., Karmakar, P., Yang, Q., Kenny, M. K., Harris, C. C., Brosh, R. M. Jr.
(2005). p53 Modulates RPA-Dependent and RPA-Independent WRN Helicase Activity. Cancer Res.
65: 1223-1233
[Abstract]
[Full Text]
-
Zhan, M., Yu, D., Liu, J., Hannay, J., Pollock, R. E.
(2005). Transcriptional Repression of Protein Kinase C{alpha} via Sp1 by Wild Type p53 Is Involved in Inhibition of Multidrug Resistance 1 P-Glycoprotein Phosphorylation. J. Biol. Chem.
280: 4825-4833
[Abstract]
[Full Text]
-
Shats, I., Milyavsky, M., Tang, X., Stambolsky, P., Erez, N., Brosh, R., Kogan, I., Braunstein, I., Tzukerman, M., Ginsberg, D., Rotter, V.
(2004). p53-dependent Down-regulation of Telomerase Is Mediated by p21waf1. J. Biol. Chem.
279: 50976-50985
[Abstract]
[Full Text]
-
Tanaka, K., Shouguchi-Miyata, J., Miyamoto, N., Ikeda, J.-E
(2004). Novel Nuclear Shuttle Proteins, HDBP1 and HDBP2, Bind to Neuronal Cell-specific cis-Regulatory Element in the Promoter for the Human Huntington's Disease Gene. J. Biol. Chem.
279: 7275-7286
[Abstract]
[Full Text]
-
Nakade, K., Zheng, H., Ganguli, G., Buchwalter, G., Gross, C., Wasylyk, B.
(2004). The Tumor Suppressor p53 Inhibits Net, an Effector of Ras/Extracellular Signal-Regulated Kinase Signaling. Mol. Cell. Biol.
24: 1132-1142
[Abstract]
[Full Text]
-
Grandori, C., Wu, K.-J., Fernandez, P., Ngouenet, C., Grim, J., Clurman, B. E., Moser, M. J., Oshima, J., Russell, D. W., Swisshelm, K., Frank, S., Amati, B., Dalla-Favera, R., Monnat, R. J. Jr.
(2003). Werner syndrome protein limits MYC-induced cellular senescence. Genes Dev.
17: 1569-1574
[Abstract]
[Full Text]
-
Opresko, P. L., Cheng, W.-H., von Kobbe, C., Harrigan, J. A., Bohr, V. A.
(2003). Werner syndrome and the fu